{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:08:12Z","timestamp":1788761292669,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Chronic myeloid leukemia is commonly treated with tyrosine kinase inhibitors, and numerous clinical trials have been conducted globally. However, the overall registration distribution, trial development patterns, and public availability of trial results remain unclear. This study aimed to map the global landscape of such trials and assess the public availability of their results.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    This registry-based cross-sectional landscape analysis searched five major public clinical trial registries up to 19 March 2026. Results availability among eligible completed trials was assessed using registry records and a supplementary bibliographic search. Two reviewers independently screened trials, extracted data, and resolved discrepancies by adjudication. Descriptive statistical analysis was conducted using R software. We focused on completed trials finished for at least 2\u00a0years to evaluate publication.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 125 trials were included, of which 96 (76.8%) were interventional studies and 23 (18.4%) were randomized. Trials were concentrated in the United States, Europe, China, and Australia. Most trials targeted BCR-ABL1 and were Phase II studies, whereas Phase I and Phase IV studies were less common. Among 52 eligible completed pharmacological trials, publicly identifiable results were available for 25 trials (48.1%). Among the 44 trials with reported clinical phase, results availability was 77.8% (7\/9) for Phase III trials and 0% (0\/4) for Phase I trials. Results availability varied descriptively across drug groups, although no drug-specific comparison remained statistically significant after adjustment for multiple testing.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Global trials are geographically and developmentally unbalanced, with incomplete public availability of trial results. Future research should strengthen international collaboration, optimize trial phase distribution, support novel agent development, and promote timely and complete public disclosure of trial results.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1904028","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:33:12Z","timestamp":1788759192000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tyrosine kinase inhibitors for chronic myeloid leukemia: a landscape analysis of global clinical trials based on public registries"],"prefix":"10.3389","volume":"17","author":[{"given":"Lichuan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiquan","family":"Wen","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zining","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Stomatology, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiebin","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia","volume":"14","author":"Amarante-Mendes","year":"2022","journal-title":"Pharmaceutics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-Targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood.2025029210","article-title":"Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial","volume":"147","author":"Cortes","year":"2026","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0140-6736(19)33220-9","article-title":"Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study","volume":"395","author":"DeVito","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1182\/blood.2024026311","article-title":"Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"145","author":"Guilhot","year":"2025","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia: a review","volume":"333","author":"Jabbour","year":"2025","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e35953","DOI":"10.1002\/cncr.35953","article-title":"Management of chronic myeloid leukemia in 2025","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e2110438","DOI":"10.1001\/jamanetworkopen.2021.10438","article-title":"Evaluation of oncology trial results reporting over a 10-Year period","volume":"4","author":"Liu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.6004\/jnccn.2017.7002","article-title":"Do published data in trials assessing cancer drugs reflect the real picture of efficacy and safety?","volume":"15","author":"Lv","year":"2017","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B16","doi-asserted-by":"publisher","first-page":"100825","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B19","volume-title":"World Population Prospects: The 2024 Revision","year":"2024"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2120165","DOI":"10.1001\/jamanetworkopen.2021.20165","article-title":"Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1186\/s12967-024-05882-5","article-title":"Drug clinical trial landscape of chronic myeloid leukemia: achieving the endpoint or continuing the journey?","volume":"22","author":"Yang","year":"2024","journal-title":"J. Transl. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1904028\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:33:14Z","timestamp":1788759194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1904028\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":21,"alternative-id":["10.3389\/fphar.2026.1904028"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1904028","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1904028"}}